Overview

Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI7352 in Healthy Volunteers

Status:
Active, not recruiting
Trial end date:
2021-11-04
Target enrollment:
Participant gender:
Summary
This study will evaluate safety, tolerability, pharmacokinetics and immunogenicity of MEDI7352 in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca